• Media type: E-Article
  • Title: Incidence, mortality, and survival analyses of patients with thymic lymphoma
  • Contributor: Wang, Li; Wang, Zhile; Huo, Lanqing; Zhao, Ailin
  • imprint: Frontiers Media SA, 2022
  • Published in: Frontiers in Oncology
  • Language: Not determined
  • DOI: 10.3389/fonc.2022.933672
  • ISSN: 2234-943X
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Objectives</jats:title><jats:p>To explore the clinical and prognostic characteristics of thymic lymphoma and the effects of current treatments on the prognosis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients diagnosed as primary thymic lymphoma between 1975 and 2018 from the nine states of the US were identified, including Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle–Puget Sound, and Utah. Incidence and mortality rates were analyzed using SEER*Stat 8.3.9 software. Univariate and multivariate Cox regressions were performed to identify prognostic factors. The Kaplan–Meier curve and log-rank test were used to compare overall survival (OS) among different treatments.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 233 patients diagnosed as thymic lymphoma were identified, and eight of them were lost to follow-up or died upon diagnosis. The incidence of thymic lymphoma was 2.032 per ten million (95% CI: 1.777–2.312), and the mortality rate was 0.649 per ten million (95% CI: 0.508–0.817). Among the 225 patients with definite follow-up, 98 were males and 127 were females, with a median age of 33 years. The Cox regression results showed that age and pathological type were independent risk prognostic factors. The 5-, 10-, and 20-year OS were 80.0%, 77.5%, and 70.9%, respectively. For Ann Arbor stage I and II patients, there was no significant difference between the surgical group (N = 78) and the non-operative group (N = 65; P = 0.270). The radiotherapy group (N = 79) had better OS than the non-radiotherapy group (N = 64) in the first 25 years, and the prognosis in the later years was not significantly different (P = 0.051). The chemotherapy group (N = 37) had a significantly better prognosis than the non-chemotherapy group (N = 37; P = 0.020). Patients who received postoperative radiotherapy (N = 45) or who only received radiotherapy (N = 34) seemed to have better OS than that of patients who only received surgery (N = 33), although the difference was not significant (P = 0.063).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Age and pathological type were independent prognostic factors for thymic lymphoma. Surgical treatment had limited effects on OS, while both radiotherapy and chemotherapy could significantly improve the survival outcome.</jats:p></jats:sec>
  • Access State: Open Access